Search Within

Neil Jayendra Shah

Formats
  1. Meeting Abstract (53)
  2. Journal Article (27)
  3. Conference Paper (1)
  4. Editorial (1)
  5. Research Letter (1)
Groups
  1. Department of Medicine (83)
  2. Genitourinary Oncology Service (83)
  3. Solid Tumor Oncology Division (83)
  4. Hematologic Malignancies, Division of (31)
  5. Weinberg Fellows (31)
  6. Population Sciences Research Program (25)

More Groups

People
  1. Robert Motzer (37)
  2. Ritesh Kotecha (26)
  3. Martin Voss (25)
  4. Maria Carlo (22)
  5. Darren Feldman (21)
  6. Chung-Han Lee (20)

More People

Years
  1. 2025 (8)
  2. 2024 (19)
  3. 2023 (22)
  4. 2022 (18)
  5. 2021 (13)
  6. 2020 (2)

More Years

Publications
  1. Journal of Clinical Oncology (44)
  2. Journal for ImmunoTherapy of Cancer (7)
  3. Cancers (4)
  4. The Oncologist (3)
  5. Annals of Oncology (2)
  6. Cancer (2)

More Publications

Publishers
  1. American Society of Clinical Oncology (46)
  2. Biomed Central Ltd (7)
  3. Oxford University Press (6)
  4. MDPI (5)
  5. American Association for Cancer Research (3)
  6. American Medical Association (2)

More Publishers

Results (83)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Real-world treatment patterns and clinical outcomes among patients with metastatic renal cell carcinoma post-immune-oncology and vascular endothelial growth factor receptor targeted therapies
    Journal Article

    Shah, N. J.; Sura, S.; Shinde, R.; Shi, J.; Bupathi, M.; Vickery, D.; Motzer, R. J.
    Cancers (2025)

    Fulltext@MSK | Save
  • A phase 1b, open-label, safety, tolerability, and efficacy study of HC-7366 in combination with belzutifan in patients with advanced or metastatic renal cell carcinoma (NCT06234605)
    Meeting Abstract

    Shah, N. J.; Bupathi, M.; Garmezy, B.; McKay, R. R.; Ornstein, M. C.; Figlin, R. A.; Picus, J.; Rank, B. H.; Barata, P. C.; Hammers, H. J.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Outcomes with first-line ipilimumab and nivolumab for patients with metastatic renal cell carcinoma by number of doses
    Meeting Abstract

    Doshi, S. D.; Sanmiguel, A. L.; Knezevic, A.; Kotecha, R. R.; Shah, N. J.; Carlo, M.; Feldman, D. R.; Motzer, R. J.; Voss, M. H.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Real-world treatment pattern and clinical outcomes among patients with metastatic renal cell (mRCC) carcinoma post PD-1/PD-L1 immuno-oncology (IO) therapies
    Meeting Abstract

    Shah, N. J.; Ravilla, R.; Osterland, A. J.; Todoroff, K.; Wang, C. Y.; Rane, P.; Saal, H.; Wang, D.; Motzer, R. J.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Real-world community oncology-based treatment patterns for first line axitinib plus pembrolizumab in advanced renal cell carcinoma: Initial dosing, dose reductions and clinical outcomes
    Meeting Abstract

    Zarrabi, K. K.; Ababio, Y.; Eccleston, A.; Rao, Drnj; Kelly, S.; Chang, J. E.; Adejumo, K. L.; Lucht, S.; Paydar, C.; Van Doren, B. A.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • DNA damage repair alterations as predictive biomarker for platinum-based chemotherapy in metastatic urothelial cancer
    Meeting Abstract

    Sternschuss, M.; Paynter, A.; Xu, W. X.; Nichols, C.; Hoppe, J.; Davis, N. B.; Jiang, D. M.; Shah, N. J.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Immune checkpoint blockade response in mucinous tubular and spindle cell carcinoma
    Journal Article

    Makker, S.; Shah, N. J.; Carlo, M. I.; Kuo, F.; Hakimi, A. A.; Chen, Y. B.; Iyer, G.; Kotecha, R. R.
    Current Oncology (2025)

    Fulltext@MSK | Save
  • Baseline colitogenicity and acute perturbations of gut microbiota in immunotherapy-related colitis
    Journal Article

    Shang, J.; Del Valle, D. M.; Britton, G. J.; Mead, K. R.; Rajpal, U.; Chen-Liaw, A.; Mogno, I.; Li, Z.; Menon, R.; Gonzalez-Kozlova, E.; more...
    Journal of Experimental Medicine (2025)

    Fulltext@MSK | Save
  • Clinical outcomes of patients with metastatic urothelial carcinoma (mUC) discontinuing enfortumab vedotin (EV) monotherapy (mono) without disease progression
    Meeting Abstract

    Sternschuss, M.; Whiting, K.; Teo, M. Y.; Bajorin, D.; Kotecha, R.; Laccetti, A. L.; Xiao, H.; Feld, E.; McHugh, D. J.; Keegan, N.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • HER2 and PD-L1 immunohistochemistry (IHC) expression, and HER2 genomic alterations: Associations and clinical outcomes for advanced bladder cancer
    Meeting Abstract

    Aggen, D. H.; Shah, N. J.; Zheng, J.; Alam, S. M.; Balar, O.; Niederhausern, A.; Regazzi, A. M.; Ratna, N.; Funt, S. A.; Teo, M. Y.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save